Clindamycin Vaginal Cream Versus Oral Metronidazole in the Treatment of Bacterial Vaginosis

1992 ◽  
Vol 85 (11) ◽  
pp. 1077-1080 ◽  
Author(s):  
FRANK J. ANDRES ◽  
REBECCA PARKER ◽  
IAN HOSEIN ◽  
GUY I. BENRUBI
Keyword(s):  
Bacterial Vaginosis ◽  
Vaginal Cream ◽  
Oral Metronidazole

Bacterial vaginosis: A comparative, double-blind study of clindamycin vaginal cream versus oral metronidazole

1993 ◽  
Vol 54 (1) ◽  
pp. 98-110 ◽  
Author(s):  
Francisco Higuera ◽  
Hilda Hidalgo ◽  
Carlos J. Sanchez ◽  
Armando Valle
Keyword(s):  
Bacterial Vaginosis ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind ◽  
Vaginal Cream ◽  
Oral Metronidazole

scholarly journals The Effect of Oral Metronidazole on the Vaginal Microbiome of Patients with Recurrent Bacterial Vaginosis: A Pilot Investigational Study

2021 ◽  
pp. 100081
Author(s):  
Oluwatosin Goje ◽  
Elizabeth O. Shay ◽  
Metabel Markwei ◽  
Roshan Padmanabhan ◽  
Charis Eng
Keyword(s):  
Bacterial Vaginosis ◽  
Vaginal Microbiome ◽  
Oral Metronidazole

Quercus brantii Lindl. Vaginal cream versus placebo on Bacterial Vaginosis: A randomized clinical trial

2019 ◽  
Vol 16 ◽  
pp. 100247 ◽  
Author(s):  
Atefeh Zare ◽  
Zeinab Moshfeghy ◽  
Mohammad M. Zarshenas ◽  
Bahia Namavar Jahromi ◽  
Marzieh Akbarzadeh ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Bacterial Vaginosis ◽  
Randomized Clinical Trial ◽  
Vaginal Cream ◽  
Quercus Brantii

scholarly journals Prognostic Indicators of Recurrence of Bacterial Vaginosis

2019 ◽  
Vol 57 (5) ◽  
Author(s):  
Jack D. Sobel ◽  
Navkiranjot Kaur ◽  
Nicole A. Woznicki ◽  
Dina Boikov ◽  
Tina Aguin ◽  
...  
Keyword(s):  
Bacterial Vaginosis ◽  
Prognostic Value ◽  
Prognostic Indicators ◽  
Recurrence Rates ◽  
Predictive Values ◽  
Prognostic Tests ◽  
Index Tests ◽  
Treatment Alternatives ◽  
Cessation Of Treatment ◽  
Oral Metronidazole

ABSTRACTFollowing all forms of therapy for bacterial vaginosis (BV), recurrence rates are extremely high. Many diagnostic tests are available that differentiate bacterial vaginosis from other types of vaginal disorders, but none predict recurrence after treatment, nor are any vetted for monitoring ongoing responses to treatment. Our goal was to determine which tests, and at what optimal times, have prognostic value in predicting recurrence. This prospective cohort study monitored 74 highly recurrent BV patients for up to 9 months. Symptomatic BV patients were treated with oral metronidazole and were evaluated at cessation of treatment and monthly. Index tests included Amsel, Nugent, BV Blue, and Affirm VPIII, as well as a quantitative PCR (qPCR)-based test under initial evaluation here. The qPCR-based LbRC (LactobacillusRelativeComposition) assay predicted BV recurrence when performed shortly after oral metronidazole treatment, with both 90% positive predictive values (PPV) and 74% negative predictive values (NPV); the Nugent scores had 93% PPV but poor NPV (57%). No test, at any other visit, was prognostic. The LbRC assay and, to a lesser extent, Nugent tests scored a week after oral metronidiazole predicted recurrence, suggesting that the recurrence in this cohort was predominantly by relapse due to incomplete restoration of eubiosis soon after therapy. This is the first study in an under evaluated population of recurrent BV patients that emphasizes the need for and a pathway to a possible prognostic modality. Given the high recurrence rates of BV, prognostic tests that could influence individualized treatment alternatives are urgently needed.

Combined vaginal administration of nystatin, diiodohydroxyquin, and benzalkonium chloride versus oral metronidazole for the treatment of bacterial vaginosis

2019 ◽  
Vol 145 (3) ◽  
pp. 261-267
Author(s):  
Wichinee Chooprasertsuk ◽  
Woraluk Somboonporn ◽  
Sukree Soontrapa ◽  
LingLing Salang ◽  
Siriruthai Amnatbuddee
Keyword(s):  
Bacterial Vaginosis ◽  
Benzalkonium Chloride ◽  
Vaginal Administration ◽  
Oral Metronidazole

scholarly journals Treating male partners of women with bacterial vaginosis (StepUp): a protocol for a randomised controlled trial to assess the clinical effectiveness of male partner treatment for reducing the risk of BV recurrence

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Lenka A. Vodstrcil ◽  
◽  
Erica L. Plummer ◽  
Michelle Doyle ◽  
Christopher K. Fairley ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Bacterial Vaginosis ◽  
Controlled Trial ◽  
Male Partner ◽  
Standard Of Care ◽  
Trial Registration ◽  
Current Standard ◽  
Randomised Controlled ◽  
Oral Metronidazole ◽  
Amsel Criteria

Abstract Background Bacterial vaginosis (BV) is estimated to affect 1 in 3 women globally and is associated with obstetric and gynaecological sequelae. Current recommended therapies have good short-term efficacy but 1 in 2 women experience BV recurrence within 6 months of treatment. Evidence of male carriage of BV-organisms suggests that male partners may be reinfecting women with BV-associated bacteria (henceforth referred to as BV-organisms) and impacting on the efficacy of treatment approaches solely directed to women. This trial aims to determine the effect of concurrent male partner treatment for preventing BV recurrence compared to current standard of care. Methods StepUp is an open-label, multicentre, parallel group randomised controlled trial for women diagnosed with BV and their male partner. Women with clinical-BV defined using current gold standard diagnosis methods (≥3 Amsel criteria and Nugent score (NS) = 4–10) and with a regular male partner will be assessed for eligibility, and couples will then be consented. All women will be prescribed oral metronidazole 400 mg twice daily (BID) for 7 days, or if contraindicated, a 7-day regimen of topical vaginal 2% clindamycin. Couples will be randomised 1:1 to either current standard of care (female treatment only), or female treatment and concurrent male partner treatment (7 days of combined antibiotics - oral metronidazole tablets 400 mg BID and 2% clindamycin cream applied topically to the glans penis and upper shaft [under the foreskin if uncircumcised] BID). Couples will be followed for up to 12 weeks to assess BV status in women, and assess the adherence, tolerability and acceptability of male partner treatment. The primary outcome is BV recurrence defined as ≥3 Amsel criteria and NS = 4–10 within 12 weeks of enrolment. The estimated sample size is 342 couples, to detect a 40% reduction in BV recurrence rates from 40% in the control group to 24% in the intervention group within 12 weeks. Discussion Current treatments directed solely to women result in unacceptably high rates of BV recurrence. If proven to be effective the findings from this trial will directly inform the development of new treatment strategies to impact on BV recurrence. Trial registration The trial was prospectively registered on 12 February 2019 on the Australian and New Zealand Clinical Trial Registry (ACTRN12619000196145, Universal Trial Number: U1111–1228-0106, https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=376883&isReview=true).

scholarly journals BACTERIAL VAGINOSIS;

2017 ◽  
Vol 24 (02) ◽  
pp. 252-257
Author(s):  
Faiqa Saleem ◽  
Munazza Malik ◽  
Muhammad Sohaib Shahid ◽  
Muhammad Tayyab
Keyword(s):  
Bacterial Vaginosis ◽  
Vaginal Discharge ◽  
Reproductive Age ◽  
P Value ◽  
Vaginal Infections ◽  
Vaginal Gel ◽  
Vaginal Cream ◽  
Significant Difference ◽  
Group A ◽  
Group B

In women of reproductive age bacterial vaginosis is a most common polymicrobialdisease and is the leading reason for vaginal discharge in this age group. Additionally itis further linked with sizeable disease burden of community problem in terms of infectiouscomplications. Clindamycin vaginal cream and metronidazole vaginal gel are effective in themanagement of vaginal infections caused by multi bacteria. Objectives: To compare thetherapeutic efficacy of Metronidazole vaginal gel and clindamycin vaginal cream as modality oftreatment for bacterial vaginosis. Study Design: Randomized control trial. Setting: Departmentof Obstetrics and Gynaecology, Unit-3 Jinnah Hospital Lahore. Period: Six months from 02-05-2011 to 01-11-2011. Material & Methods: A total of 300 patients were included in this study.They were divided into two groups. Group A received metronidazole vaginal gel (5 g dailyfor 7 days) while group B administered with clindamycin vaginal cream (5g daily for 7 days).Results: Mean age of the patient was observed 34.3+3.5 and 32.9+ 2.1 years in group –A andB respectively. Vaginal discharge was absent in 104 patients (69.3%) from group A and 127(84.7%) from group-B. Absence of clue cells on microscopy revealed in 112 patients (74.7%)from group A and 137 patients (91.3%) from group B. Absence of amine odour found in 116patients (77.3%) of group A and 134 patients (89.3%) of group B. Significant difference wasfound between two groups with p value of 0.006 in respect of efficacy. Conclusion: Clindamycinvaginal cream is more effective in comparison to Metronidazole vaginal gel for the treatment ofbacterial vaginosis.

scholarly journals BACTERIAL VAGINOSIS; COMPARISON BETWEEN METRONIDAZOLE VAGINAL GEL AND CLINDAMYCIN VAGINAL CREAM FOR TREATMENT OF BACTERIAL VAGINOSIS

2017 ◽  
Vol 24 (02) ◽  
pp. 252-257
Author(s):  
Dr. Faiqa Saleem ◽  
Dr. Munazza Malik ◽  
Dr. Muhammad Shahid ◽  
Prof. Muhammad Tayyab
Keyword(s):  
Bacterial Vaginosis ◽  
Vaginal Gel ◽  
Vaginal Cream
Sign in / Sign up

Export Citation Format

Share Document